The correlations between IL-17 vs. Th17 cells and cancer patient survival: A systematic review

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-10

  Punt, Simone ^a   Langenhoff, Jessica M ^a   Putter, H ^a   Fleuren, Gert Jan ^a   Gorter, Arko ^a   Jordanova, Ekaterina S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; IL 17; Survival; Th17; Tumor microenvironment

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 17; RETINOIC ACID RECEPTOR GAMMA; TUMOR NECROSIS FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CD4+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LEUKEMIA; META ANALYSIS (TOPIC); OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; TH17 CELL; TUMOR PROMOTION;

EID: 84954566376     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.984547     Document Type: Article

References (80)

1. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned, from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150:5445-56; PMID:8390535.
2. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-76; PMID: 15485625; http://dx.doi.org/10.1016/j.immuni.2004.08.018
3. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19:652-7; PMID: 17766098; http://dx.doi.org/10.1016/j.coi.2007.07.020
4. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40; PMID: 15657292; http://dx.doi.org/10.1084/jem.20041257
5. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-7; PMID: 18563156; http://dx.doi.org/10.1038/nature07036
6. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11:763-76; PMID:23023676; http://dx.doi.org/10.1038/nrd3794
7. Cua DJ, Tato CM. Innate IL-17-producing cells:the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89; PMID:20559326; http://dx.doi.org/10.1038/nri2800
8. Hirota K, Ahlfors H, Duarte JH, Stockinger B. Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep 2012; 13:113-20; PMID:22193778; http://dx.doi.org/10.1038/embor.2011.248
9. Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 2011; 6:e24048; PMID:21887369; http://dx.doi.org/71/journal.pone.0024048
10. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2009; 2:403-11; PMID: 19587639; http://dx.doi.org/10.1038/mi.2009.100
11. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 2013; 182:10-20; PMID:23159950; http://dx.doi.org/10.1016/j.ajpath.2012.08.041
12. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W. Th17 cells in cancer:help or hindrance? Carcinogenesis 2011; 32:643-9; PMID:21304053; http://dx.doi.org/10.1093/carcin/bgr019
13. Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, Chen M, Sung JJ, Hu P. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer 2010; 127:86-92; PMID: 19904747; http://dx.doi.org/10.1002/ijc.25027
14. Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW. FOXP3 and CTLA4 over expression in multiple myeloma bone marrow as a sign of accumulation of CD4 T regulatory cells. Cancer Immunol Immun. other 2014; 63:1189-97; PMID:25099367; http://dx.doi.org/10.1007/s00262-014-1589-9
15. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010; 69:348-54; PMID:20022135; http://dx.doi.org/10.1016/j.lungcan.2009.11.013
16. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407:348-54; PMID:21396350; http://dx.doi.org/10.1016/j.bbrc.2011.03.021
17. Yamada Y, Saito H, Ikeguchi M. Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res 2012; 178:685-91; PMID:22940035; http://dx.doi.org/10.1016/j.jss.2012.07.055
18. Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32:3; PMID:23305119; http://dx.doi.org/10.1186/1756-9966-32-3
19. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50:980-9; PMID: 19329213; http://dx.doi.org/10.1016/j.jhep.2008.12.033
20. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, Th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907
21. Yu Q, Lou XM, He Y. Prediction of local recurrence in cervical cancer by a Cox model comprised of lymph node status, lymph-vascular space invasion, and intratumoral Th17 cell-infiltration. Med Oncol 2014; 31:795; PMID:24310812; http://dx.doi.org/10.1007/s12032-013-0795-1
22. Lin SZ, Chen KJ, Xu ZY, Chen H, Zhou L, Xie HY, Zheng SS. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. Cancer Prev Res (Phila) 2013; 6:594-602; PMID:23599540; http://dx.doi.org/10.1158/1940-6207.CAPR-12-0379
23. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J, Liu J. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013; 352:351-9; PMID=23397428; http://dx.doi.org/10.1007/s0044l-013-1567-0
24. Tseng JY, Yang CY, Liang SC, Liu RS, Yang SH, Lin JK, Chen YM, Wu YC, Jiang JK, Lin CH. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res 2014; 20:2885-97; PM ID:24677375; http://dx.doi.org/10.1158/1078-0432.CCR-13-2162
25. Xu C, Hao K, Yu L, Zhang X. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers 2014; 19:287-90; PMID:24731052; http://dx.doi.org/10.3109/1354750X.20l4.908954
26. Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One 2012; 7:e50035; PMID:23227158; http://dx.doi.org/10.1371/journal.pone.0050035
27. Xu C, Yu L, Zhan P, Zhang Y. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Eur J Med Res 2014; 19:23; PMID=24887477; http://dx.doi.org/10.1186/2047-783X-19-23
28. Droeser RA, Guth U, Eppenberger-Castori S, Stadlmann S, Hirt C, Terracciano L, Singer G. High IL-17-positive tumor immune cell infiltration is indicative for chemo sensitivity of ovarian carcinoma. J Cancer Res Clin Oncol 2013; 139:1295-302; PMID:23624523; http://dx.doi.org/10.1007/s00432-013-1441-1
29. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2:616-31; PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-14-0027
30. Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histo pathology 2013; 63:225-33; PMID:23738752; http://dx.doi.org/10.1111/his.12156
31. Cho BS, Lim JY, Yahng SA, Lee SE, Eom KS, Kim YJ, Chung NG, Jeong DC, Lee S, Kim HJ et al. Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. Ann Hematol 2012; 91:439-48; PMID=21894475; http://dx.doi.org/10.1007/s00277-011-1318-9
32. Abousamra NK, Salah El-Din M, Helal R. Prognostic value of Th17 cells in acute leukemia. Med Oncol 2013; 30:732; PMID:24085544; http://dx.doi.org/10.1007/s12032-013-0732-3
33. Hus I, Bojarska-Junak A, Chocholska S, Tomczak W, Wos J, Dmoszynska A, Rolinski J. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. PLoS One 2013; 8:e78091; PMID:24223764; http://dx.doi.org/10.1371/journal.pone.0078091
34. Yan XJ, Dozmorov I, Li W, Yancopoulos S, Sison C, Centola M, Jain P, Allen SL, Kolitz JE, Rai KR et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011; 118:5201-10; PMID:21911837; http://dx.doi.org/10.1182/blood-2011-03-342436
35. Song XN, Yang JZ, Sun LX, Meng JB, Zhang JQ, Lv HY, Kong LJ. Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival. Leuk Res 2013; 37:1094-9; PMID:23849453; http://dx.doi.org/10.1016/j.leukres.2013.06.022
36. Vizio B, Novarino A, Giacobino A, Cristiano C, Prati A, Ciuffreda L, Montrucchio G, Bellone G. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med 2012; 4:70-78; PMID:23060925; http://dx.doi.org/10.3892/etm.2012.553
37. Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES, Gorter A. Angels and demons:Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncolmmunology 2015; 4: e984539; http://dx.doi.org/10.4l61/2162402X.2014.984539
38. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 2012; 97:599-607; PMID:22058222; http://dx.doi.org/10.3324/haematol.2011.047316
39. Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, Xu J, Rao H, Chen S, Zhang L et al. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother 2013; 62:1575-85; PMID:23912243; http://dx.doi.org/10.1007/s00262-013-1460-4
40. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 2011; 10:150; PMID:22171994; http://dx.doi.org/10.1186/1476-4598-10-150
41. Yan J, Liu XL, Xiao G, Li NL, Deng YN, Han LZ, Yin LC, Ling LJ, Liu LX. Prevalence and clinical relevance of T-helper cells, Th17 and Thl, in hepatitis B virus-related hepatocellular carcinoma. PLoS One 2014; 9: e96080; PMID:24867183; http://dx.doi.org/10.1371/journal.pone.0096080
42. Huang Y, Wang F, Wang Y, Zhu Z, Gao Y, Ma Z, Xu R, Du Z. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29:851-9; PMID:24303990; http://dx.doi.org/10.1111/jgh.12418
43. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 2011; 6:e21816; PMID:21760911; http://dx.doi.org/10.1371/journal.pone.0021816
44. Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J et al. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2012; 19:2506-14; PMID:22411204; http://dx.doi.org/10.1245/s10434-012-2268-8
45. Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 2014; 31:82; PMID:25034363; http://dx.doi.org/10.1007/s12032-0l4-0082-9
46. Zhang GQ, Han F, Fang XZ, Ma XM. CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis. Asian Pac J Cancer Prev 2012; 13:3955-60; PMID:23098499; http://dx.doi.org/10.7314/apjcp.2012.13.8.3955
47. Zhang Y, Huang Y, Qin M. Tumour-infiltrating FoxP3+ and IL-17-producing T cells affect the progression and prognosis of gallbladder carcinoma after surgery. Scand J Immunol 2013; 78:516-22; PMID:24007242; http://dx.doi.org/10.1111/sji.12109
48. He S, Fei M, Wu Y, Zheng D, Wan D, Wang L, Li D. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 2011; 12:7424-37; PMID:22174607; http://dx.doi.org/10.3390/ijmsl2117424
49. Wang Y, Yang J, Xu H. [Expression of IL-17 in laryngeal squamous cell carcinoma tissues and the clinical significance]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013; 27:779-83; PMID:24l67997.
50. Liu X, Jin H, Zhang G, Lin X, Chen C, Sun J, Zhang Y, Zhang Q, Yu J. Intratumor IL-17-Positive Mast Cells Are the Major Source of the IL-17 That Is Predictive of Survival in Gastric Cancer Patients. PLoS One 2014; 9:e106834; PMID:25197971; http://dx.doi.org/10.1371/journal.pone.0106834
51. Chen JG, Xia JC, Liang XT, Pan K, Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 2011; 7:53-60; PMID:21234303; http://dx.doi.org/10.7150/ijbs.7.53
52. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011; 6:e18219; PMID:21483813; http://dx.doi.org/10.1371/journal.pone.0018219
53. Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, Zeng YX. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010; 9:4; PMID:20064222; http://dx.doi.org/10.1186/1476-4598-9-4
54. Xu M, Song Z-G, Xu C-X, Rong G-H, Fan K-X, Chen J-Y, Zhang W, Jia J-P, Han G, Wang W et al. IL-17A stimulates the progression of giant cell tumors of bone. Clinical Cancer Research 2013; 19:4697-705; PMID:23857601; http://dx.doi.org/10.1158/1078-0432.CCR-13-0251
55. Lin Y, Xu J, Su H, Zhong W, Yuan Y, Yu Z, Fang Y, Zhou H, Li C, Huang K. Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol 2014; 17:50-6; PMID:25015721; http://dx.doi.org/10.1007/s12094-014-1197-3
56. Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q, Qin J, Hao L, Wang Z, Shen L et al. Analysis of CD 1371 and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci 2013; 9:134-41; PMID:23411595; http://dx.doi.org/10.7150/ijbs.4891
57. Cui G, Yang H, Zhao J, Yuan A, Florholmen J. Elevated Pro inflammatory Cytokine IL-17A in the Adjacent Tissues Along the Adenoma-Carcinoma Sequence. Pathol Oncol Res 2014; 21:139-46; PMID:24859972; http://dx.doi.org/10.1007/s12253-0l4-9799-1
58. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001; 282:735-8; PMID: 11401524; http://dx.doi.org/10.1006/bbrc.2001.4618
59. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012; 77:918-25; PMID:22738343; http://dx.doi.org/10.1111/j.1365-2265.2012.04482.x
60. Liao Y, Wang B, Huang ZL, Shi M, Yu XJ, Zheng L, Li S, Li L. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma:a prospective study. PLoS One 2013; 8:e60444; PMID:23565248; http://dx.doi.org/10.1371/journal.pone.0060444
61. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011; 17:896-906; PMID:21106722; http://dx.doi.org/10.1158/1078-0432.CCR-10-2463
62. Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X, Chen W, Cheng P, Wang T, Chen N et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol 2012; 32:1332-9; PMID:22760549; http://dx.doi.org/10.1007/sl0875-012-9718-8
63. Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, Lin HC. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer 2013; 133:2895-902; PMID:23749461; http://dx.doi.org/10.1002/ijc.28060
64. Wang HT, Zhao XY, Zhao XS, Han TT, Lv M, Chang YJ, Huang XJ. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2013; 34:679-84; PMID:23978019; http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2013.08.008
65. Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M et al. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-a but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. Clin Cancer Res 2014; 20:4390-9; PMID:24938524; http://dx.doi.org/10.1158/1078-0432.CCR-l4-1015
66. Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and IL-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci 2014; 105:933-42; PMID:24890519; http://dx.doi.org/10.1111/cas.12459
67. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 2010; 185:6348-54; PMID:20952674; http://dx.doi.org/10.4049/jimmunol.1001728
68. Gong Y, Chen SX, Gao BA, Yao RC, Guan L. Cell origins and significance of IL-17 in malignant pleural effusion. Clin Transl Oncol 2014; 16:807-13; PMID:24399072; http://dx.doi.org/10.1007/s12094-013-1152-8
69. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114:1141-9; PMID: 19470694; http://dx.doi.org/10.1182/blood-2009-03-208249
70. Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, Naka T, Ojima T, Ueda K, Hayata K et al. Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection. Oncol Rep 2014; 31:605-12; PMID:24337702; http://dx.doi.org/10.3892/or.2013.2911
71. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours:impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
72. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol 1999; 66:989-95; PMID: 10614782.
73. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Inter-leukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7; PMID: 12411307; http://dx.doi.org/10.1182/blood-2002-05-1461
74. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE, Linden A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162:2347-52; PMID:9973514.
75. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx.doi.org/10.1158/0008-5472.CAN-10-2583
76. Benchetrit F, Ciree A, Vives V, Warmer G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21; PMID: 11877287; http://dx.doi.org/10.1182/blood:V99.6.2114
77. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer:the ultimate identity crisis. Front Immunol 2014; 5:276; PMID:24987392; http://dx.doi.org/10.3389/fimmu.2014.00276
78. Ji Y, Zhang W. Th17 cells:positive or negative role in tumor? Cancer Immunol Immunother 2010; 59:979-87; PMID:20352428; http://dx.doi.org/10.1007/s00262-010-0849-6
79. De Simone V, Pallone F, Monteleone G, Stolfi C. Role of T17 cytokines in the control of colorectal cancer. Oncoimmunology 2013; 2:e26617; PMID:24498548; http://dx.doi.org/10.4161/onci.26617
80. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. Ann Intern Med 2009; 151:264-9, W64; PMID: 19622511; http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00135